Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Rhea-AI Summary

Adverum Biotechnologies (ADVM), a clinical-stage company focused on gene therapy for ocular diseases, has announced its participation in three upcoming investor conferences:

• H.C. Wainwright 26th Annual Global Investment Conference on September 10th at 3:30 p.m. ET
• Chardan's 8th Annual Genetic Medicines Conference on October 1st at 8:00 a.m. ET
• UBS Virtual Ophthalmology Day on October 2nd at 10:30 a.m. ET

On-demand webcasts of these presentations will be available in the Investors section of Adverum's website under Events and Presentations. Replays will be accessible for at least 30 days following each event.

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences:

• H.C. Wainwright 26^th Annual Global Investment Conference on Tuesday, September 10^th at 3:30 p.m. ET.
• Chardan’s 8^th Annual Genetic Medicines Conference on Tuesday, October 1^st at 8:00 a.m. E.T.
• UBS Virtual Ophthalmology Day on Wednesday, October 2^nd at 10:30 a.m. ET.
  

The on-demand webcasts may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of each webcast will be available on the website for at least 30 days following the events.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.

Inquiries:
Adverum Investor Relations
Email: ir@adverum.com

FAQ

What investor conferences is Adverum Biotechnologies (ADVM) attending in Fall 2024?

Adverum Biotechnologies is attending three investor conferences: H.C. Wainwright Global Investment Conference on September 10th, Chardan's Genetic Medicines Conference on October 1st, and UBS Virtual Ophthalmology Day on October 2nd, 2024.

When is Adverum Biotechnologies (ADVM) presenting at the H.C. Wainwright Conference?

Adverum Biotechnologies is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10th, 2024, at 3:30 p.m. ET.

How can investors access Adverum Biotechnologies' (ADVM) conference presentations?

Investors can access on-demand webcasts of Adverum Biotechnologies' presentations under the Events and Presentations section in the Investors area of the company's website. Replays will be available for at least 30 days after each event.

What is the focus of Adverum Biotechnologies' (ADVM) research?

Adverum Biotechnologies is a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases.